PTAB's Doors Would Be Closed To Generics Under Hatch Bill
Proposed legislation by one of the architects of the Hatch-Waxman Act to require generics makers to choose between challenging drug patents under that law or through inter partes reviews would effectively...To view the full article, register now.
Already a subscriber? Click here to view full article